FDA ANDA · ANDA209132
CISATRACURIUM BESYLATE
Sponsor: SOMERSET
What this page does not claim
A drug page is a reference view of public FDA data (Drugs@FDA), reproduced as published. SPEQ is not affiliated with the FDA, adds no interpretation to the record, and nothing here is medical, legal, or regulatory advice.
APPLICATION
ANDA209132
TYPE
ANDA
ORIGINAL APPROVAL
2019-04-24
LATEST ACTION
2026-10-20
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription
Products
CISATRACURIUM BESYLATEPrescription
CISATRACURIUM BESYLATE EQ 2MG BASE/ML · INJECTABLE · INJECTION
Approval history
2026-10-20Labeling · Supplement 9 · standardAP
2020-05-26Labeling · Supplement 2 · standardAP
2019-04-24UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. Browse every approval SPEQ tracks →